Is Chemed (CHE) Fully Priced Following Its Recent Rally?
Chemed (CHE) has drawn investor attention after recent trading, with the stock last closing at US$510.03. That move comes alongside fresh interest in how its hospice and plumbing businesses support the current valuation.
See our latest analysis for Chemed.
Recent trading fits into a broader upswing for Chemed, with a 30 day share price return of 16.97% and a 90 day share price return of 32.61%. This contrasts with a 3 year total shareholder return that is down 8.16%, suggesting momentum has picked up recently even as longer term returns have been more modest.
If you are assessing Chemed alongside other ideas in healthcare, it could be a good moment to scan the market for companies in similar themes using the 39 healthcare AI stocks
Chemed has just sprinted higher, and investors now face a familiar fork in the road: pay up at today’s price or wait and risk missing further upside if the valuation already stacks up. Let us break that down.
Most Popular Narrative: 7.6% Overvalued
Chemed's most followed valuation narrative points to a fair value of $474, which sits below the current $510.03 share price and frames the recent rally as pricing in more than that narrative implies.
The ramp-up of new Certificate of Need (CON) locations in underserved Florida counties (e.g., Pinellas and Marion) is expected to materially expand VITAS's service footprint, aligning with the continued aging U.S. population and the shift toward home-based care, both key drivers of higher patient volumes and long-term top-line revenue growth.
Want to see how that growth story turns into a specific fair value for Chemed? The narrative leans heavily on higher margins, steadier earnings and a lower P/E than the stock trades on today.
Result: Fair Value of $474 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Chemed's heavy exposure to Medicare reimbursement rules and weaker residential demand at Roto Rooter could still disrupt the margin story that investors are watching.
Find out about the key risks to this Chemed narrative.
Another View: What Chemed's P/E Is Signalling
While one Chemed narrative focuses on a fair value of $474, the current P/E of 26x tells a mixed story. It is slightly above the US Healthcare industry at 25.5x and above a fair ratio of 24.4x, yet well below peer levels around 98.6x. This raises the question: is the market overpaying or leaving upside on the table?
To see how this valuation gap could close in either direction, it helps to look at the detailed breakdown of earnings, peer multiples and the fair ratio in context. You can do this through the See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With Chemed showing both enthusiasm and caution in recent data, now is the moment to review the full picture and decide where you stand, starting with the 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond Chemed?
If Chemed has sharpened your focus, do not stop here. Broader context from other stocks can help you stress test your thesis and spot missed opportunities.
- Spot potential bargains by scanning 47 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their financial profile.
- Prioritise resilience by reviewing 84 resilient stocks with low risk scores that score well on balance sheet strength and business stability.
- Get ahead of the crowd by using the screener containing 20 high quality undiscovered gems before attention and liquidity potentially shift toward these businesses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com